November 2016November 2016
New Product - Adempas
Adempas (riociguat) is a stimulator of soluble guanylate cyclase (sGC), an enzyme found in most tissues and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyses synthesis of the signalling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Riociguat has a dual mode of action. It sensitises sGC to endogenous NO by stabilising the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat restores the NO-sGC-cGMP pathway and leads to increased generation of cGMP. Adempas is indicated for the following. 1) Pulmonary arterial hypertension: as monotherapy or in combination with approved PAH treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of: idiopathic pulmonary arterial hypertension; heritable pulmonary arterial hypertension; pulmonary arterial hypertension associated with connective tissue diseases or; pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, lll or IV symptoms. 2) Chronic thromboembolic pulmonary hypertension: indicated for the treatment of: persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or; inoperable CTEPH, in adult patients with WHO functional Class II, lll or IV symptoms. Adempas is contraindicated during pregnancy and lactation; in women of childbearing potential who may become pregnant and not using reliable contraception Women must not become pregnant for at least 1 month after stopping treatment with Adempas. Also coadministration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated. Coadministration of Adempas with specific PDE-5-inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (such as dipyridamole or theophylline) is contraindicated. Adempas is contraindicated in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP). Adempas is available as 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg tablets in packs of 42’s and 84’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au